Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: A retrospective study of US public and private health care claims

Postgraduate Medicine

Volumn 126, Issue 5, 2014, Pages 113-120

  Khemiri, Amine ^a   Kharitonova, Elizaveta ^a   Zah, Vladimir ^b   Ruby, Jane ^c   Toumi, Mondher ^d  

^a CREATIV CEUTICAL   (France)

^b ZRX OUTCOMES RESEARCH INC   (Canada)

^c RECKITT BENCKISER   (United Kingdom)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Buprenorphine naloxone; Dosing level; Health care costs; Opioid dependence; Resource utilization

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; NALOXONE;

ADULT; AGE; COMORBIDITY; DOSE RESPONSE; ECONOMICS; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; INSURANCE; KAPLAN MEIER METHOD; MALE; MEDICATION COMPLIANCE; MENTAL DISORDERS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RECURRENT DISEASE; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADULT; AGE FACTORS; BUPRENORPHINE; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MENTAL DISORDERS; NALOXONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84921806393     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.09.2805     Document Type: Article

References (10)

1. Package Insert for Suboxone Sublingual Film. Richmond, VA: Reckitt Benckiser, 2014.
2. Fareed A, Vayalapalli S, Casarella J, Drexler K. Effect of Buprenorphine dose on treatment outcome. J Addictive Dis. 2012;31(1):8-18.
3. Greenwald M, Johanson C, Moody D, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropscyhopharmacology. 2003;28(11):2000-2009.
4. National Institute of Drug Abuse. Understanding Drug Abuse and Addiction: What Science Says. 2007. http://www.drugabuse.gov/ publications/teaching-packets/understanding-drug-abuse-addiction/ section-iv/6-cost-effectiveness-drug-treatment. Accessed July 2014.
5. Clay E, Khemiri A, Zah V, Ruby J, Asche C. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence [published online ahead of print June 6, 2014]. J Med Econ. doi:10.3111/136969 98.2014.925463.
6. Kharitonova E, Clay E, Ruby J, Aballea S, Zah V. Retrospective study of persistence and healthcare charges among opioid-dependent patients treated with buprenorphine/naloxone film and tablet formulations using a privately insured retrospective database. Paper presented at the 25th Annual Academy of Managed Care Pharmacy Meeting and Expo, April 3-6, 2013, San Diego, CA.
7. Kharitonova E, Clay E, Ruby J, Aballea S, Zah V. Retrospective study of persistence and healthcare charges among opioid-dependent patients treated with buprenorphine/naloxone film and tablet formulations using a privately insured retrospective database. Paper presented at the 44th Annual Medical Scientific Conference of American Society of Addiction Medicine, April 25-28, 2013, Chicago, IL.
8. Optum insight. Clinformatics Data Mart. 2014. http://www.optuminsight. com/life-sciences/solutions/value-strategy/marketing-analytics/ clinformatics-data-mart///media/Ingenix/Life_Sciences/Documents/ OptumInsightLifeSciencesClinformaticsDataMart_old.pdf. Accessed July 2014.
9. National Center for Health Statistics (NCHS) and the Centers for Medicare and Medicaid Services. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). 2013. http://www. cdc.gov/nchs/icd/icd9cm.htm. Accessed July 2014.
10. Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17(Suppl 8):S235-S248.